These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24099307)

  • 21. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
    Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
    Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoinflammatory markers and disease activity in systemic lupus erythematosus: something old, something new.
    Elwy MA; Galal ZA; Hasan HE
    East Mediterr Health J; 2010 Aug; 16(8):893-900. PubMed ID: 21469572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.
    Uribe AG; Vilá LM; McGwin G; Sanchez ML; Reveille JD; Alarcón GS
    J Rheumatol; 2004 Oct; 31(10):1934-40. PubMed ID: 15468356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.
    Jacobi AM; Odendahl M; Reiter K; Bruns A; Burmester GR; Radbruch A; Valet G; Lipsky PE; Dörner T
    Arthritis Rheum; 2003 May; 48(5):1332-42. PubMed ID: 12746906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic lupus erythematosus: a review of the disease and treatment options.
    Gurevitz SL; Snyder JA; Wessel EK; Frey J; Williamson BA
    Consult Pharm; 2013 Feb; 28(2):110-21. PubMed ID: 23395811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of systemic lupus erythematosus.
    Lam GK; Petri M
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S120-32. PubMed ID: 16273796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus.
    Yang DH; Chang DM; Lai JH; Lin FH; Chen CH
    Rheumatology (Oxford); 2009 Sep; 48(9):1083-7. PubMed ID: 19553377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
    Wang M; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):833-7. PubMed ID: 22290935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of interferon-α as a biomarker in central neuropsychiatric involvement in systemic lupus erythematosus.
    Fragoso-Loyo H; Atisha-Fregoso Y; Núñez-Alvarez CA; Llorente L; Sánchez-Guerrero J
    J Rheumatol; 2012 Mar; 39(3):504-9. PubMed ID: 22247358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VH4-34 encoded antibodies in systemic lupus erythematosus: a specific diagnostic marker that correlates with clinical disease characteristics.
    van Vollenhoven RF; Bieber MM; Powell MJ; Gupta PK; Bhat NM; Richards KL; Albano SA; Teng NN
    J Rheumatol; 1999 Aug; 26(8):1727-33. PubMed ID: 10451069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus.
    Hawker G; Gabriel S; Bombardier C; Goldsmith C; Caron D; Gladman D
    J Rheumatol; 1993 Apr; 20(4):657-60. PubMed ID: 8496860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
    Urbonaviciute V; Voll RE
    J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.
    Wollaston SJ; Farewell VT; Isenberg DA; Gordon C; Merrill JT; Petri MA; Kalunian KC;
    J Rheumatol; 2004 Dec; 31(12):2390-4. PubMed ID: 15570639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic syndrome is associated with increased arterial stiffness and biomarkers of subclinical atherosclerosis in patients with systemic lupus erythematosus.
    Sabio JM; Vargas-Hitos J; Zamora-Pasadas M; Mediavilla JD; Navarrete N; Ramirez A; Hidalgo-Tenorio C; Jáimez L; Martín J; Jiménez-Alonso J;
    J Rheumatol; 2009 Oct; 36(10):2204-11. PubMed ID: 19723903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.
    Sciascia S; Ceberio L; Garcia-Fernandez C; Roccatello D; Karim Y; Cuadrado MJ
    Autoimmun Rev; 2012 Dec; 12(2):157-63. PubMed ID: 22498788
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of nailfold capillaroscopy in systemic lupus erythematosus: correlation with endothelial cell activation markers and disease activity.
    Kuryliszyn-Moskal A; Ciolkiewicz M; Klimiuk PA; Sierakowski S
    Scand J Rheumatol; 2009; 38(1):38-45. PubMed ID: 18991188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased Fas and Bcl-2 expression on peripheral mononuclear cells from patients with active juvenile-onset systemic lupus erythematosus.
    Liphaus BL; Kiss MH; Carrasco S; Goldenstein-Schainberg C
    J Rheumatol; 2007 Jul; 34(7):1580-4. PubMed ID: 17516614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the disease activity core set.
    Ruperto N; Ravelli A; Cuttica R; Espada G; Ozen S; Porras O; Sztajnbok F; Falcini F; Kasapcopur O; Venning H; Bica B; Merino R; Coto C; Ros J; Susic G; Gamir ML; Minden K; See Y; Uziel Y; Mukamel M; Riley P; Zulian F; Olivieri AN; Cimaz R; Girschick H; Rumba I; Cavuto S; Pistorio A; Lovell DJ; Martini A; ;
    Arthritis Rheum; 2005 Sep; 52(9):2854-64. PubMed ID: 16142708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.